Regulation of human T cell responses by dNP2-ctCTLA-4 inhibits human skin and microvessel graft rejection

Rudoll, 1996, High-efficiency retroviral vector mediated gene transfer into human peripheral blood CD4+ T lymphocytes, Gene Ther., 3, 695 Cherkassky, 2016, Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition, J. Clin. Invest., 126, 3130, 10.1172/JCI83092 Zhao, 2006, High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation, Mol. Ther., 13, 151, 10.1016/j.ymthe.2005.07.688 Ferber, 2001, Gene therapy. Safer and virus-free?, Science, 294, 1638, 10.1126/science.294.5547.1638 Guidotti, 2017, Cell-Penetrating peptides: from basic research to clinics, Trends Pharmacol. Sci., 38, 406, 10.1016/j.tips.2017.01.003 Warso, 2013, A first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours, Br. J. Canc., 108, 1061, 10.1038/bjc.2013.74 Abes, 2007, Cell-penetrating-peptide-based delivery of oligonucleotides: an overview, Biochem. Soc. Trans., 35, 775, 10.1042/BST0350775 Bates, 2008, Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction, Circulation, 117, 886, 10.1161/CIRCULATIONAHA.107.759167 Cirak, 2011, Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study, Lancet, 378, 595, 10.1016/S0140-6736(11)60756-3 Heeger, 2003, T-cell allorecognition and transplant rejection: a summary and update, Am. J. Transplant.: Off. J. Am. Soc. Transplant. Am. Soc. Transplant Surg., 3, 525, 10.1034/j.1600-6143.2003.00123.x Colombo, 2011, Cyclosporine in transplantation - a history of converging timelines, J. Biol. Regul. Homeost. Agents, 25, 493 Rath, 2013, Tacrolimus in transplant rejection, Expet Opin. Pharmacother., 14, 115, 10.1517/14656566.2013.751374 Pape, 2014, mTOR inhibitors in pediatric kidney transplantation, Pediatr. Nephrol., 29, 1119, 10.1007/s00467-013-2505-9 Sollinger, 1995, Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group, Transplantation, 60, 225, 10.1097/00007890-199508000-00003 Holt, 2017, Overview of immunosuppressive therapy in solid organ transplantation, Anesthesiol. Clin., 35, 365, 10.1016/j.anclin.2017.04.001 Cosimi, 1981, Treatment of acute renal allograft rejection with OKT3 monoclonal antibody, Transplantation, 32, 535, 10.1097/00007890-198112000-00018 Vincenti, 1998, Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group, N. Engl. J. Med., 338, 161, 10.1056/NEJM199801153380304 Basu, 2005, Reversal of acute cellular rejection after renal transplantation with Campath-1H, Transplant. Proc., 37, 923, 10.1016/j.transproceed.2004.12.019 Mahmud, 2010, Antibody immunosuppressive therapy in solid-organ transplant: Part I, mAbs, 2, 148, 10.4161/mabs.2.2.11159 Satyananda, 2014, Belatacept in kidney transplantation, Curr. Opin. Organ Transplant., 19, 573, 10.1097/MOT.0000000000000134 Walunas, 1994, CTLA-4 can function as a negative regulator of T cell activation, Immunity, 1, 405, 10.1016/1074-7613(94)90071-X Krummel, 1995, CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation, J. Exp. Med., 182, 459, 10.1084/jem.182.2.459 Chikuma, 2005, B7-independent inhibition of T cells by CTLA-4, J. Immunol., 175, 177, 10.4049/jimmunol.175.1.177 Stumpf, 2013, The B7-independent isoform of CTLA-4 functions to regulate autoimmune diabetes, J. Immunol., 190, 961, 10.4049/jimmunol.1201362 Wing, 2008, CTLA-4 control over Foxp3+ regulatory T cell function, Science, 322, 271, 10.1126/science.1160062 Lim, 2015, dNP2 is a blood-brain barrier-permeable peptide enabling ctCTLA-4 protein delivery to ameliorate experimental autoimmune encephalomyelitis, Nat. Commun., 6, 8244, 10.1038/ncomms9244 Pober, 2003, Immunopathology of human T cell responses to skin, artery and endothelial cell grafts in the human peripheral blood lymphocyte/severe combined immunodeficient mouse, Springer Semin. Immunopathol., 25, 167, 10.1007/s00281-003-0135-1 Murray, 1994, Human T-cell-mediated destruction of allogeneic dermal microvessels in a severe combined immunodeficient mouse, Proc. Natl. Acad. Sci. U. S. A., 91, 9146, 10.1073/pnas.91.19.9146 Kirkiles-Smith, 2004, IL-11 protects human microvascular endothelium from alloinjury in vivo by induction of survivin expression, J. Immunol., 172, 1391, 10.4049/jimmunol.172.3.1391 Zheng, 2004, Bcl-2 transduction protects human endothelial cell synthetic microvessel grafts from allogeneic T cells in vivo, J. Immunol., 173, 3020, 10.4049/jimmunol.173.5.3020 Lim, 2016, Cell type preference of a novel human derived cell-permeable peptide dNP2 and TAT in murine splenic immune cells, PLoS One, 11, 10.1371/journal.pone.0155689 Nakase, 2012, Accumulation of arginine-rich cell-penetrating peptides in tumors and the potential for anticancer drug delivery in vivo, J. Contr. Release, 159, 181, 10.1016/j.jconrel.2012.01.016 Kreisel, 2002, Non-hematopoietic allograft cells directly activate CD8+ T cells and trigger acute rejection: an alternative mechanism of allorecognition, Nat. Med., 8, 233, 10.1038/nm0302-233 Murray, 1998, Dermal microvascular injury in the human peripheral blood lymphocyte reconstituted-severe combined immunodeficient (HuPBL-SCID) mouse/skin allograft model is T cell mediated and inhibited by a combination of cyclosporine and rapamycin, Am. J. Pathol., 153, 627, 10.1016/S0002-9440(10)65604-0 Shiao, 2005, Memory T cells and their costimulators in human allograft injury, J. Immunol., 175, 4886, 10.4049/jimmunol.175.8.4886 Koh, 2004, T cell-mediated vascular dysfunction of human allografts results from IFN-gamma dysregulation of NO synthase, J. Clin. Invest., 114, 846, 10.1172/JCI21767 Jin, 2013, IL-17 cytokines in immunity and inflammation, Emerg. Microb. Infect., 2, e60 Mae, 2006, Cell-penetrating peptides as vectors for peptide, protein and oligonucleotide delivery, Curr. Opin. Pharmacol., 6, 509, 10.1016/j.coph.2006.04.004 Huang, 2015, Delivery of nucleic acids and nanomaterials by cell-penetrating peptides: opportunities and challenges, BioMed Res. Int., 2015, 834079 Benichou, 2011, Immune recognition and rejection of allogeneic skin grafts, Immunotherapy, 3, 757, 10.2217/imt.11.2 Herrera, 2004, A novel pathway of alloantigen presentation by dendritic cells, J. Immunol., 173, 4828, 10.4049/jimmunol.173.8.4828 Fangmann, 1993, Rejection of skin allografts by indirect allorecognition of donor class I major histocompatibility complex peptides, Transplant. Proc., 25, 183 Benichou, 1992, Donor major histocompatibility complex (MHC) peptides are presented by recipient MHC molecules during graft rejection, J. Exp. Med., 175, 305, 10.1084/jem.175.1.305 Boisgerault, 2000, Induction of T-cell response to cryptic MHC determinants during allograft rejection, Hum. Immunol., 61, 1352, 10.1016/S0198-8859(00)00209-3 Benichou, 2017, Role of memory T cells in allograft rejection and tolerance, Front. Immunol., 8, 170, 10.3389/fimmu.2017.00170 Shiao, 2007, Human effector memory CD4+ T cells directly recognize allogeneic endothelial cells in vitro and in vivo, J. Immunol., 179, 4397, 10.4049/jimmunol.179.7.4397 Sullivan, 2014, The emerging role of TH17 cells in organ transplantation, Transplantation, 97, 483, 10.1097/TP.0000000000000000 Yoshida, 2006, Anti-type V collagen lymphocytes that express IL-17 and IL-23 induce rejection pathology in fresh and well-healed lung transplants, Am. J. Transplant.: Off. J. Am. Soc. Transplant. Am. Soc. Transplant Surg., 6, 724, 10.1111/j.1600-6143.2006.01236.x Vergani, 2013, Long-term heart transplant survival by targeting the ionotropic purinergic receptor P2X7, Circulation, 127, 463, 10.1161/CIRCULATIONAHA.112.123653 Haynes, 2012, Donor-specific indirect pathway analysis reveals a B-cell-independent signature which reflects outcomes in kidney transplant recipients, Am. J. Transplant.: Off. J. Am. Soc. Transplant. Am. Soc. Transplant Surg., 12, 640, 10.1111/j.1600-6143.2011.03869.x Zhang, 2017, Knockout of microRNA-155 ameliorates the Th1/Th17 immune response and tissue injury in chronic rejection, J. Heart Lung Transplant.: Off. Pub. Int. Soc. Heart Transplant., 36, 175, 10.1016/j.healun.2016.04.018 Peddi, 2013, Review of combination therapy with mTOR inhibitors and tacrolimus minimization after transplantation, Transplant. Rev. (Orlando), 27, 97, 10.1016/j.trre.2013.06.001 Aguero, 2008, Influence of immunosuppressive regimens on short-term morbidity and mortality in heart transplantation, Clin. Transplant., 22, 98 Knechtle, 2003, Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study, Am. J. Transplant.: Off. J. Am. Soc. Transplant. Am. Soc. Transplant Surg., 3, 722, 10.1034/j.1600-6143.2003.00120.x Galian, 2016, Molecular targets on B-cells to prevent and treat antibody-mediated rejection in organ transplantation. Present and Future, Expert Opin. Ther. Targets, 20, 859, 10.1517/14728222.2016.1135904 Vincenti, 2005, Costimulation blockade with belatacept in renal transplantation, N. Engl. J. Med., 353, 770, 10.1056/NEJMoa050085 Bassil, 2014, Prospective monitoring of cytomegalovirus, Epstein-Barr virus, BK virus, and JC virus infections on belatacept therapy after a kidney transplant, Exp. Clin. Transplant. Official J. Middle East Soc. Organ Transplant., 12, 212 Levitsky, 2013, Inhibitory effects of belatacept on allospecific regulatory T-cell generation in humans, Transplantation, 96, 689, 10.1097/TP.0b013e31829f1607 Schneider, 1995, CTLA-4 binding to the lipid kinase phosphatidylinositol 3-kinase in T cells, J. Exp. Med., 181, 351, 10.1084/jem.181.1.351 Marengere, 1996, Regulation of T cell receptor signaling by tyrosine phosphatase SYP association with CTLA-4, Science, 272, 1170, 10.1126/science.272.5265.1170 Chikuma, 2000, Janus kinase 2 is associated with a box 1-like motif and phosphorylates a critical tyrosine residue in the cytoplasmic region of cytotoxic T lymphocyte associated molecule-4, J. Cell. Biochem., 78, 241, 10.1002/(SICI)1097-4644(20000801)78:2<241::AID-JCB7>3.0.CO;2-K Srahna, 2006, CTLA-4 interacts with STAT5 and inhibits STAT5-mediated transcription, Immunology, 117, 396, 10.1111/j.1365-2567.2005.02313.x Kong, 2014, Protein kinase C-eta controls CTLA-4-mediated regulatory T cell function, Nat. Immunol., 15, 465, 10.1038/ni.2866 Choi, 2006, Intranasal delivery of the cytoplasmic domain of CTLA-4 using a novel protein transduction domain prevents allergic inflammation, Nat. Med., 12, 574, 10.1038/nm1385 Lim, 2017, dNP2-ctCTLA-4 inhibits German cockroach extract-induced allergic airway inflammation and hyper-responsiveness via inhibition of Th2 responses, Exp. Mol. Med., 49, e362, 10.1038/emm.2017.107 Choi, 2008, Transduction of the cytoplasmic domain of CTLA-4 inhibits TcR-specific activation signals and prevents collagen-induced arthritis, Proc. Natl. Acad. Sci. U. S. A., 105, 19875, 10.1073/pnas.0805198105